Oslo, Norway, 3 June 2022: Reference is made to the stock exchange release by
Photocure ASA ("Photocure" or the "Company") published on 1 June 2022 regarding
initiation of a share buyback program.

The Company has completed its share buyback program. The Company has acquired a
total of 36,000 own shares at a price per share of NOK 102.072. A report of all
the transactions relating to the buy-back programme, in a detailed form and in
an aggregated form is attached.

The shares acquired is used for the Company's incentive scheme and sold to
employees.

After the acquisition and sale to employees, Photocure owns 14,641 own shares in
the Company.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is made public by the Company pursuant to the EU Market Abuse
Regulation article 5, as supplemented by Commission Delegated Regulation (EU)
2016/1052, and is subject to the disclosure requirements pursuant to Section 5
-12 the Norwegian Securities Trading Act.